Ilkka Mononen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ilkka Mononen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Eira Kelo
Clinical Chemistry University of Kuopio Kuopio Finland
2 shared publications- Tiina Noronkoski
Department of Clinical Chemistry, Kuopio University Hospital, Finland
2 shared publications Ulla Dunder
Eastern Finland Laboratory Centre, Kuopio, Finland
2 shared publicationsDimiter D Petkov
Laboratory of Biocatalysis, Institute of Organic Chemistry, Bulgarian Academy of Sciences, BG-1113 Sofia, Bulgaria
1 shared publicationDimiter D. Petkov
1 shared publicationEeva-Liisa Romppanen
Kuopio University Hospital, Department of Clinical Chemistry, Finland
1 shared publication
Latest Publications
- 6 July 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (5) , 611-617
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice
Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology in many somatic tissues, but has only limited efficacy in the brain tissue of the animals. In the current work, ERT of AGU mice was initiated at the age of 1 week with three different dosage schedules of recombinant glycosylasparaginase. The animals received either 3.4 U of AGA/kg every second day for 2 weeks (Group 1), 1.7 U/kg every second day for 9 days followed by an enzyme injection once a week for 4 weeks (Group 2) or 17 U/kg at the age of 7 and 9 days (Group 3). In the Group 1 and Group 3 mice, ERT reduced the amount of aspartylglucosamine by 34 and 41% in the brain tissue, respectively. No therapeutic effect was observed in the brain tissue of Group 2 mice. As in the case of adult AGU mice, the AGA therapy was much more effective in the somatic tissues than in the brain tissue of the newborn AGU mice. The combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease.
- 6 July 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (5) , 611-617
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice
Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology in many somatic tissues, but has only limited efficacy in the brain tissue of the animals. In the current work, ERT of AGU mice was initiated at the age of 1 week with three different dosage schedules of recombinant glycosylasparaginase. The animals received either 3.4 U of AGA/kg every second day for 2 weeks (Group 1), 1.7 U/kg every second day for 9 days followed by an enzyme injection once a week for 4 weeks (Group 2) or 17 U/kg at the age of 7 and 9 days (Group 3). In the Group 1 and Group 3 mice, ERT reduced the amount of aspartylglucosamine by 34 and 41% in the brain tissue, respectively. No therapeutic effect was observed in the brain tissue of Group 2 mice. As in the case of adult AGU mice, the AGA therapy was much more effective in the somatic tissues than in the brain tissue of the newborn AGU mice. The combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease.
- Open Access
- 25 August 2004
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 15 (1) , 79-85
Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy
Aspartylglycosaminuria (AGU) is caused by deficient enzymatic activity of glycosylasparaginase (GA). The disease is characterized by accumulation of aspartylglucosamine (GlcNAc-Asn) and other glycoasparagines in tissues and body fluids of AGU patients and in an AGU mouse model. In the current study, we characterized a glycoasparagine carrying the tetrasaccharide moiety of α-D-Man-(1→6)-β-D-Man-(1→4)-β-D-GlcNAc-(1→4)-β-D-GlcNAc-(1→N)-Asn (Man2GlcNAc2-Asn) in urine of an AGU patient and also in the tissues of the AGU mouse model. Quantitative analysis demonstrated a massive accumulation of the compound especially in nonneuronal tissues of the AGU mice, in which the levels of Man2GlcNAc2-Asn were typically 30–87% of those of GlcNAc-Asn. The highest level of Man2GlcNAc2-Asn was found in the liver, spleen, and heart tissues of the AGU mice, the respective amounts being 87%, 76%, and 57% of the GlcNAc-Asn levels. In the brain tissue of AGU mice the Man2GlcNAc2-Asn storage was only 9% of that of GlcNAc-Asn. In contrast to GlcNAc-Asn, the storage of Man2GlcNAc2-Asn markedly increased in the liver and spleen tissues of AGU mice as they grew older. Enzyme replacement therapy with glycosylasparaginase for 3.5 weeks reduced the amount of Man2GlcNAc2-Asn by 66–97% in nonneuronal tissues, but only by 13% in the brain tissue of the AGU mice. In conclusion, there is evidence for a role for storage of glycoasparagines other than aspartylglucosamine in the pathogenesis of AGU, and this possibility should be taken into consideration in the treatment of the disease.
- 25 August 2004
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 15 (1) , 79-85
Open AccessMassive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy
Aspartylglycosaminuria (AGU) is caused by deficient enzymatic activity of glycosylasparaginase (GA). The disease is characterized by accumulation of aspartylglucosamine (GlcNAc-Asn) and other glycoasparagines in tissues and body fluids of AGU patients and in an AGU mouse model. In the current study, we characterized a glycoasparagine carrying the tetrasaccharide moiety of α-D-Man-(1→6)-β-D-Man-(1→4)-β-D-GlcNAc-(1→4)-β-D-GlcNAc-(1→N)-Asn (Man2GlcNAc2-Asn) in urine of an AGU patient and also in the tissues of the AGU mouse model. Quantitative analysis demonstrated a massive accumulation of the compound especially in nonneuronal tissues of the AGU mice, in which the levels of Man2GlcNAc2-Asn were typically 30–87% of those of GlcNAc-Asn. The highest level of Man2GlcNAc2-Asn was found in the liver, spleen, and heart tissues of the AGU mice, the respective amounts being 87%, 76%, and 57% of the GlcNAc-Asn levels. In the brain tissue of AGU mice the Man2GlcNAc2-Asn storage was only 9% of that of GlcNAc-Asn. In contrast to GlcNAc-Asn, the storage of Man2GlcNAc2-Asn markedly increased in the liver and spleen tissues of AGU mice as they grew older. Enzyme replacement therapy with glycosylasparaginase for 3.5 weeks reduced the amount of Man2GlcNAc2-Asn by 66–97% in nonneuronal tissues, but only by 13% in the brain tissue of the AGU mice. In conclusion, there is evidence for a role for storage of glycoasparagines other than aspartylglucosamine in the pathogenesis of AGU, and this possibility should be taken into consideration in the treatment of the disease.
- 28 August 2002
- Published by Wiley in FEBS Letters
- Vol. 528 (1-3) , 130-132
β‐Aspartylpeptides as substrates of L‐asparaginases from Escherichia coli and Erwinia chrysanthemi
L‐Asparaginase is known to catalyze the hydrolysis of L‐asparagine to L‐aspartic and ammonia, but little is known about its action on peptides. When we incubated L‐asparaginases purified either from Escherichia coli or Erwinia chrysanthemi – commonly used as chemotherapeutic agents because of their antitumour activity – with eight small β‐aspartylpeptides such as β‐aspartylserineamide, β‐aspartylalanineamide, β‐aspartylglycineamide and β‐aspartylglycine, we found that both L‐asparaginases could catalyze the hydrolysis of five of them yielding L‐aspartic acid and amino acids or peptides. Our data show that L‐asparaginases can hydrolyze β‐aspartylpeptides and suggest that L‐asparaginase therapy may affect the metabolism of β‐aspartylpeptides present in human body.
- 28 August 2002
- Published by Wiley in FEBS Letters
- Vol. 528 (1-3) , 130-132
β‐Aspartylpeptides as substrates of L‐asparaginases from Escherichia coli and Erwinia chrysanthemi
L‐Asparaginase is known to catalyze the hydrolysis of L‐asparagine to L‐aspartic and ammonia, but little is known about its action on peptides. When we incubated L‐asparaginases purified either from Escherichia coli or Erwinia chrysanthemi – commonly used as chemotherapeutic agents because of their antitumour activity – with eight small β‐aspartylpeptides such as β‐aspartylserineamide, β‐aspartylalanineamide, β‐aspartylglycineamide and β‐aspartylglycine, we found that both L‐asparaginases could catalyze the hydrolysis of five of them yielding L‐aspartic acid and amino acids or peptides. Our data show that L‐asparaginases can hydrolyze β‐aspartylpeptides and suggest that L‐asparaginase therapy may affect the metabolism of β‐aspartylpeptides present in human body.
- Open Access
- 14 June 2001
- Published by Wiley in FEBS Letters
- Vol. 499 (1-2) , 77-81
Human leukocyte glycosylasparaginase: cell‐to‐cell transfer and properties in correction of aspartylglycosaminuria
Aspartylglycosaminuria (AGU), a severe lysosomal storage disease, is caused by the deficiency of the lysosomal enzyme, glycosylasparaginase (GA), and accumulation of aspartylglucosamine (GlcNAc‐Asn) in tissues. Here we show that human leukocyte glycosylasparaginase can correct the metabolic defect in Epstein–Barr virus (EBV)‐transformed AGU lymphocytes rapidly and effectively by mannose‐6‐phosphate receptor‐mediated endocytosis or by contact‐mediated cell‐to‐cell transfer from normal EBV‐transformed lymphocytes, and that 2–7% of normal activity is sufficient to correct the GlcNAc‐Asn metabolism in the cells. Cell‐to‐cell contact is obligatory for the transfer of GA since normal transformed lymphocytes do not excrete GA into extracellular medium. The combined evidence indicates that cell‐to‐cell transfer of GA plays a main role in enzyme replacement therapy of AGU by normal lymphocytes.
- 14 June 2001
- Published by Wiley in FEBS Letters
- Vol. 499 (1-2) , 77-81
Open AccessHuman leukocyte glycosylasparaginase: cell‐to‐cell transfer and properties in correction of aspartylglycosaminuria
Aspartylglycosaminuria (AGU), a severe lysosomal storage disease, is caused by the deficiency of the lysosomal enzyme, glycosylasparaginase (GA), and accumulation of aspartylglucosamine (GlcNAc‐Asn) in tissues. Here we show that human leukocyte glycosylasparaginase can correct the metabolic defect in Epstein–Barr virus (EBV)‐transformed AGU lymphocytes rapidly and effectively by mannose‐6‐phosphate receptor‐mediated endocytosis or by contact‐mediated cell‐to‐cell transfer from normal EBV‐transformed lymphocytes, and that 2–7% of normal activity is sufficient to correct the GlcNAc‐Asn metabolism in the cells. Cell‐to‐cell contact is obligatory for the transfer of GA since normal transformed lymphocytes do not excrete GA into extracellular medium. The combined evidence indicates that cell‐to‐cell transfer of GA plays a main role in enzyme replacement therapy of AGU by normal lymphocytes.
- Open Access
- 1 June 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (6) , 811-816
Detection of the Finnish-Type Congenital Nephrotic Syndrome by Restriction Fragment Length Polymorphism and Dual-Color Oligonucleotide Ligation Assays
Background: Congenital nephrotic syndrome of Finnish type (NPHS1) is an autosomal recessive disorder characterized by severe proteinuria of intrauterine onset. Ninety-four percent of the Finnish NPHS1 chromosomes have been reported to carry either a 2-bp deletion in exon 2 (FinMajor) or a nonsense mutation in exon 26 (FinMinor) of the NPHS1 gene. The high prevalence of only two mutations in the Finnish population enables the use of molecular techniques in the diagnosis of NPHS1 and for carrier screening. Methods and Results: We describe two different molecular methods for the detection of the NPHS1 mutations: a PCR-restriction fragment length polymorphism (PCR-RFLP) and a dual-color oligonucleotide ligation assay (OLA). The dual-color OLA, which enables simultaneous detection of the NPHS1 FinMajor and FinMinor mutations, can be used for rapid analysis of large sets of samples. The analysis of 2004 Finnish blood samples revealed 34 carriers of the FinMajor mutation and 1 carrier of the FinMinor mutation, indicating a carrier frequency of 1:59 (95% confidence interval, 1:89–1:44) for the NPHS1 FinMajor mutation and 1:2004 (95% confidence interval, 0 to 1:677) for the NPHS1 FinMinor mutation, respectively. Conclusion: PCR-RFLP and dual-color OLA are suitable for molecular diagnosis and carrier screening of the major mutations that cause NPHS1.
- 1 June 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (6) , 811-816
Open AccessDetection of the Finnish-Type Congenital Nephrotic Syndrome by Restriction Fragment Length Polymorphism and Dual-Color Oligonucleotide Ligation Assays
Background: Congenital nephrotic syndrome of Finnish type (NPHS1) is an autosomal recessive disorder characterized by severe proteinuria of intrauterine onset. Ninety-four percent of the Finnish NPHS1 chromosomes have been reported to carry either a 2-bp deletion in exon 2 (FinMajor) or a nonsense mutation in exon 26 (FinMinor) of the NPHS1 gene. The high prevalence of only two mutations in the Finnish population enables the use of molecular techniques in the diagnosis of NPHS1 and for carrier screening. Methods and Results: We describe two different molecular methods for the detection of the NPHS1 mutations: a PCR-restriction fragment length polymorphism (PCR-RFLP) and a dual-color oligonucleotide ligation assay (OLA). The dual-color OLA, which enables simultaneous detection of the NPHS1 FinMajor and FinMinor mutations, can be used for rapid analysis of large sets of samples. The analysis of 2004 Finnish blood samples revealed 34 carriers of the FinMajor mutation and 1 carrier of the FinMinor mutation, indicating a carrier frequency of 1:59 (95% confidence interval, 1:89–1:44) for the NPHS1 FinMajor mutation and 1:2004 (95% confidence interval, 0 to 1:677) for the NPHS1 FinMinor mutation, respectively. Conclusion: PCR-RFLP and dual-color OLA are suitable for molecular diagnosis and carrier screening of the major mutations that cause NPHS1.
- 17 January 1996
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 218 (2) , 510-513
Enzymatic Synthesis of the N-Glycosidic Bond by β-Aspartylation of Glycosylamines
- 17 January 1996
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 218 (2) , 510-513
Enzymatic Synthesis of the N-Glycosidic Bond by β-Aspartylation of Glycosylamines